Who We Are
We are on a mission to transform the treatment of heart failure through deployment of next-generation cellular medicines. Our expert leadership team brings deep scientific know-how, regulatory and clinical trials experience as well as commercial insight to develop and bring to market ground-breaking therapies that regenerate damaged cardiac tissue.
HISTORY
Our History
Over the past decade we have assembled a team of experienced biotech executives, built a robust IP-backed epigenetic cell reprogramming platform and advanced our lead cell therapy candidate (CLXR-001) toward a pivotal Phase II / III trial due to begin in H1, 2026. Today, Cardiogeni stands at the forefront of innovation, bridging Nobel-level science and clinical ambition to deliver therapies that aim to regenerate damaged heart tissue and change the lives of heart failure patients worldwide.
2016
A New Horizon
Cardiogeni Ltd Incorporated to exploit powerful Phase 2a clinical data treating patients with New York Stage III and IV heart failure.
2017
Pharma Validation
Development and license agreement with major Japanese Pharma yielding $20M up-front payment, 9 figure development milestones and $6.5M equity investment.
2022 / 23
RCT Clinical Trial
Your con
Randomised Controlled Trial initated in EU jurisdiction and first patients dosed. Interim blinded data showed good safety with no adverse events.
2024 / 25
From IP to IPO
Cardiogeni makes preparations and then lists on the Aquis Stock Exchange raising ~£1M in new funding to progress its corporate development.
2026
Cardiogeni (UAE) JV
Foundation of Cardiogeni Ltd (UAE) with investment partners contributing clinical, regulatory expertise and (pending binding funding agreement completion) upto £20M in funding. JV is undertaking a pivotal Phase 2b clinical trial to gain approval of its lead heart failure medicine for the GCC region.
Our Team
Cardiogeni is led by an experienced executive team with deep expertise in biotechnology, pre-clinical R&D, gaining regulatory approvals, clinical development and commercial strategy. Bringing together decades of leadership across global life-science organisations, our team is committed to advancing breakthrough cellular medicines that address all stages from heart failure from scientific discovery to real-world patient impact.
Dr Darrin M Disley OBE
Executive Chairman
Darrin is a scientist, entrepreneur, investor and enterprise champion who has started, grown, or invested in over 40 start-up enterprises, with significant fundraising and deal-making experience. He was a co-founder and CEO of Horizon Discovery Group Plc a company he led from start-up through a $113M IPO on AIM and onto be a global leader in gene editing with a market cap of over $500M.
Professor Sir Martin Evans
Chief Scientific Officer
Professor Sir Martin Evans was the first scientist to identify embryonic stem cells, which can be adapted for a wide variety of medical purposes. He won the 2007 Nobel Prize for medicine along with Mario Capecchi and Oliver Smithies for their pioneering work in gene editing and cell reprogramming.
Ajan Reginald
Executive Director
Ajan is an experienced biotechnology CEO with a track record in drug development, biotech transactions and commercialisation. He has served as the Global Head of Emerging Technologies for Roche Group and Business Development Director, Roche Pharmaceuticals; Chief Operating Officer and Chief Technology Officer of Novacyt S.A and CEO of Roquefort Therapeutics PLC.
Professor Joanne Martin
Non-Executive Director
Professor Martin graduated from Cambridge University and London Hospital Medical College, has a University of London PhD and a Masters in Leadership. She has over 130 published papers including Nature group and Science journals and is Deputy Vice Principal (Health) and Professor of Pathology at Queen Mary University London.
Chaim Hurvits
Non-Executive Director
Chaim currently serves as the CEO of CH Health, a private venture capital firm, a position he has held since May 2011, and as a non-executive director of NRX Pharmaceuticals Inc (NASDAQ: NRXP). He is a serial entrepreneur leading and investing in healthcare companies that have gone on to be listed in Isreal, London and NASDAQ.
Lord James Bethell
Non-Executive Director
Lord Bethell is an entrepreneur, former health minister and champion for public health. He has a twenty-year track record working across government, media and industry, working at The Sunday Times, the US Senate, the EU Commission and the British government.